布地奈德福莫特罗与异丙托溴铵联合用药方案治疗稳定期SCOPD的临床评价

2016-07-23阚鸿雁

中国卫生标准管理 2016年8期

阚鸿雁

阚鸿雁

【摘要】目的探究布地奈德福莫特罗与异丙托溴铵联合治疗稳定期重度慢性阻塞性肺疾病（Severe Chronic Obstructive Pulmonary Disease，SCOPD）的临床疗效，为临床合理用药提供参考。方法选取稳定期SCOPD患者120例，采用分段随机化法分为A组和B组，每组各60例；A组给予布地奈德福莫特罗与异丙托溴铵联合用药方案，B组仅单纯应用布地奈德福莫特罗治疗，对比两组SCOPD患者的治疗效果。结果两组SCOPD患者肺功能、血气指标相比，治疗前差异无统计学意义（P＞0.05）；治疗后各项指标均较治疗前有改善（P＜0.05），且A组优于B组（P＜0.05）。结论布地奈德福莫特罗与异丙托溴铵联合用药方案的临床价值高，可改善SCOPD患者的临床症状，且不良反应较少，安全有效。

【关键词】慢性阻塞性肺疾病；布地奈德福莫特罗；异丙托溴铵；联合用药方案

Objective To explore clinical efficacy of budesonide formoterol combined with ipratropium bromide in the treatment of severe chronic obstructivepulmonary disease（SCOPD）at stable phase，and to provide reference for rational drug use in the clinic. Methods 120 cases with stable SCOPD were selected，they were randomly devided into group A and group B，each group had 60 cases. Group A was given budesonide formoterol and ipratropium bromide combined regimen care. In group B，only budesonide formoterol was used，the clinical efficacy was compared between the two groups. Results There was no significant difference in the lung function and blood gas indexes between the two groups before treatment（P＞0.05）. All indexes were improved after treatment than before treatment（P＜0.05）.In group A，the improvement degree of lung function and blood gas indexes was better than that in group B after treatment（P＜ 0.05）. Conclusion Clinical efficacy of budesonide formoterol combined with ipratropium bromide in the treatment of SCOPD at stable phase is remarkable. It can significantly improve the clinical symptoms，and with less adverse reactions，is safe and effective.

【Key words】 Severe chronic obstructive pulmonary disease，Stable phase，Budesonide formoterol，Ipratropium bromide，Combination therapy

SCOPD属于呼吸系统疾病，具有较高的死亡率以及发病率［1］，SCOPD患者常伴有全身系统疾病，患者的气流受限以及气道炎症等因素会导致患者出现运动耐力、精神状态以及呼吸生理功能差的情况，威胁患者的生命安全。目前，治疗SCOPD的主要方法是使用支气管扩张剂改善患者的症状，布地奈德福莫特罗与异丙托溴铵均属于器官舒张的常用药物，在SCOPD患者治疗中具有一定的价值。本文针对布地奈德福莫特罗与异丙托溴铵联合用药方案治疗SCOPD稳定期的临床价值作分析，内容如下文。